Drugs & Targets FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test August 09, 2024Vol.50 No.32
Trials & Tribulations Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC August 02, 2024Vol.50 No.31By Donald A. Berry
Drugs & Targets FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma August 02, 2024Vol.50 No.31
Drugs & Targets FDA approves Shield blood test for colon cancer screening August 02, 2024Vol.50 No.31
Drugs & Targets FDA grants Priority Review to Scemblix for newly-diagnosed Ph+ CML-CP August 02, 2024Vol.50 No.31
Drugs & Targets Expanded access program opens in the U.S. for TLX101-CDx, Telix’s investigational glioma imaging agent August 02, 2024Vol.50 No.31
Regulatory News ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications July 26, 2024Vol.50 No.30By Jacquelyn Cobb and Paul Goldberg
Drugs & Targets FDA clears IND for Zymeworks’ antibody drug conjugate ZW191 July 26, 2024Vol.50 No.30
